BAYER AG |
Market Closed -
Other stock markets
|
After market 03:59:57 pm | |||
| 19.50 EUR | +1.25% |
|
19.50 | +0.02% |
| 08:33pm | Bayer competitor Corteva wants to significantly expand its soybean business in Brazil | DP |
| Dec. 03 | BAYER AG : JP Morgan reaffirms its Neutral rating | ZD |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Nitrogenous Fertilizers | ||||||||||
Crop Science | 19.85B | 18.85B | 20.22B | 25.18B | 23.29B | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -1.41B | -1.32B | -1.24B | -1.79B | -1.6B | |||||
EBITDA | 4.8B | 4.54B | 4.7B | 6.87B | 5.04B | |||||
D&A | 2.75B | 2.69B | 2.26B | 4.6B | 2.37B | |||||
Operating Income | 2B | 1.79B | -495M | 2.95B | -3.49B | |||||
Pharmaceutical Products | ||||||||||
Pharmaceuticals | 17.99B | 17.29B | 18.37B | 19.26B | 18.11B | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -974M | -1.39B | -1.31B | -1.32B | -1.21B | |||||
EBITDA | 5.98B | 6.02B | 5.78B | 5.87B | 5.19B | |||||
D&A | 1.06B | 954M | 871M | 1.23B | 908M | |||||
Operating Income | 4.9B | 5.03B | 4.47B | 4.98B | 3.97B | |||||
Non-Prescription Drugs | ||||||||||
Consumer Health | 5.47B | 5.05B | 5.29B | 6.08B | 6.03B | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -222M | -170M | -207M | -200M | -171M | |||||
EBITDA | 1.09B | 1.11B | 1.19B | 1.37B | 1.41B | |||||
D&A | 358M | 320M | 331M | 364M | 361M | |||||
Operating Income | 731M | 793M | 808M | 957M | 1.16B | |||||
Outsourced Business Services | ||||||||||
All Other | 2.65B | 372M | 203M | 219M | 239M | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -283M | -66M | -93M | -43M | -105M | |||||
EBITDA | 293M | 178M | 95M | 151M | 163M | |||||
D&A | 256M | 69M | 69M | 71M | 67M | |||||
Operating Income | 38M | - | -27M | 79M | 96M | |||||
Enabling Functions and Consolidation | -2.42B | -163M | -5M | -1M | -36M | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -27M | -199M | -156M | -293M | -241M | |||||
EBITDA | -651M | -383M | -583M | -745M | -95M | |||||
D&A | 15M | 246M | 212M | 245M | 201M | |||||
Operating Income | -666M | -632M | -1.4B | -1.96B | -1.13B | |||||
Total Assets | - | - | - | - | - | |||||
Plastic and Synthetic Resins | ||||||||||
Covestro | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBITDA | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Veterinary Drugs | ||||||||||
Animal Health | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBITDA | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 13.56B | 12.88B | 13.4B | 15.68B | 14.59B | |||||
Total Assets | 53.89B | 43.38B | 48B | 46.24B | 39.52B | |||||
Europe / Middle East / Africa (Excl. Germany & Switzerland) | 10.32B | 10.02B | 10.56B | 11.35B | 11.07B | |||||
Total Assets | 4.3B | 3.97B | 4.28B | 4.79B | 4.46B | |||||
Brazil | 3.54B | 2.99B | 3.48B | 5.32B | 4.97B | |||||
Total Assets | 2.55B | 1.65B | 1.63B | 1.84B | 1.47B | |||||
Asia / Pacific (Excl.China) | 4.88B | 4.78B | 4.99B | 5.19B | 4.74B | |||||
Total Assets | 1.52B | 1.32B | 1.31B | 1.2B | 969M | |||||
Latin America (Excl. Brazil) | 3.12B | 2.91B | 3.16B | 3.97B | 3.96B | |||||
Total Assets | 1.22B | 1.02B | 1.22B | 1.44B | 1.3B | |||||
China | 3.73B | 3.48B | 3.86B | 4.26B | 3.62B | |||||
Total Assets | 554M | 588M | 623M | 675M | 695M | |||||
Germany | 2.36B | 2.36B | 2.54B | 2.48B | 2.45B | |||||
Total Assets | 15.27B | 15.34B | 15.46B | 15.17B | 15.2B | |||||
North America (Excl.United States) | 1.53B | 1.47B | 1.56B | 1.89B | 1.67B | |||||
Total Assets | 1.7B | 1.42B | 1.58B | 1.48B | 1.06B | |||||
Switzerland | 505M | 496M | 542M | 600M | 567M | |||||
Total Assets | 5.31B | 5.12B | 4.93B | 4.66B | 4.32B | |||||
Europe / Middle East / Africa | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Latin America | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Latin America / Africa / Middle East | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Asia / Pacific | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Reconciliation | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
North America | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Europe | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - |
- Stock Market
- Equities
- BAYN Stock
- Financials Bayer AG
- Business Segments